Trevi Therapeutics Inc (NASDAQ: TRVI)’s stock price has plunge by -8.53relation to previous closing price of 6.51. Nevertheless, the company has seen a -5.33% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-02 that Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
The 36-month beta value for TRVI is at 0.60. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 59.67M, and currently, shorts hold a 11.51% of that float. The average trading volume for TRVI on June 02, 2025 was 2.32M shares.
TRVI’s Market Performance
The stock of Trevi Therapeutics Inc (TRVI) has seen a -5.33% decrease in the past week, with a -13.70% drop in the past month, and a 39.79% gain in the past quarter. The volatility ratio for the week is 2.00%, and the volatility levels for the past 30 days are at 2.75% for TRVI. The simple moving average for the last 20 days is -7.01% for TRVI stock, with a simple moving average of 38.10% for the last 200 days.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with H.C. Wainwright repeating the rating for TRVI by listing it as a “Buy.” The predicted price for TRVI in the upcoming period, according to H.C. Wainwright is $21 based on the research report published on May 28, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $29, previously predicting the price at $9. The rating they have provided for TRVI stocks is “Strong Buy” according to the report published on March 10th, 2025.
Needham gave a rating of “Buy” to TRVI, setting the target price at $25 in the report published on March 10th of the current year.
TRVI Trading at -5.30% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.42% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from SCIASCIA THOMAS, who sale 2,631 shares at the price of $6.60 back on Mar 25 ’25. After this action, SCIASCIA THOMAS now owns 221,373 shares of Trevi Therapeutics Inc, valued at $17,365 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 5,263 shares at $6.58 during a trade that took place back on Mar 21 ’25, which means that GOOD JENNIFER L is holding 213,313 shares at $34,625 based on the most recent closing price.
Stock Fundamentals for TRVI
The total capital return value is set at -0.51. Equity return is now at value -55.12, with -51.03 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -43.12. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17029.67.
Currently, EBITDA for the company is -51.52 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.38.
Conclusion
In conclusion, Trevi Therapeutics Inc (TRVI) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
